These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 38837219

  • 1. Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli.
    Öztaş S, Er DK, Dündar D, Keçeli SA.
    Acta Microbiol Immunol Hung; 2024 Jul 02; 71(2):110-120. PubMed ID: 38837219
    [Abstract] [Full Text] [Related]

  • 2. Occurrence of multi-carbapenemase-producing Enterobacterales in a tertiary hospital in Madrid (Spain): A new epidemiologic scenario.
    Cabello M, Hernández-García M, Maruri-Aransolo A, Michelena M, Pérez-Viso B, Ponce-Alonso M, Cantón R, Ruiz-Garbajosa P.
    J Glob Antimicrob Resist; 2024 Sep 02; 38():281-291. PubMed ID: 38996870
    [Abstract] [Full Text] [Related]

  • 3. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
    Hoşbul T, Aydoğan CN, Kaya S, Bedir O, Gümral R, Albay A.
    Mikrobiyol Bul; 2022 Apr 02; 56(2):218-229. PubMed ID: 35477226
    [Abstract] [Full Text] [Related]

  • 4. Dynamic evolution of ceftazidime-avibactam resistance from a single patient through the IncX3_NDM-5 plasmid transfer and blaKPC mutation.
    Tang C, Shen S, Yang W, Shi Q, Ding L, Han R, Hu F.
    Int J Antimicrob Agents; 2024 Aug 02; 64(2):107228. PubMed ID: 38823494
    [Abstract] [Full Text] [Related]

  • 5. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
    Papadimitriou-Olivgeris M, Bartzavali C, Lambropoulou A, Solomou A, Tsiata E, Anastassiou ED, Fligou F, Marangos M, Spiliopoulou I, Christofidou M.
    J Antimicrob Chemother; 2019 Jul 01; 74(7):2051-2054. PubMed ID: 31002313
    [Abstract] [Full Text] [Related]

  • 6. Ceftazidime-Avibactam resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae: A phenotypic and genotypic analysis.
    Krithika VM, Ganesan V, Rajendran T.
    Indian J Med Microbiol; 2024 Jul 01; 49():100603. PubMed ID: 38705276
    [Abstract] [Full Text] [Related]

  • 7. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
    Maraki S, Mavromanolaki VE, Magkafouraki E, Moraitis P, Stafylaki D, Kasimati A, Scoulica E.
    Infection; 2022 Apr 01; 50(2):467-474. PubMed ID: 34854060
    [Abstract] [Full Text] [Related]

  • 8. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M, Doyle TB, Hubler C, Sader HS, Mendes RE.
    Int J Antimicrob Agents; 2020 Jul 01; 56(1):106011. PubMed ID: 32417206
    [Abstract] [Full Text] [Related]

  • 9. Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.
    Wilhelm CM, Antochevis LC, Magagnin CM, Arns B, Vieceli T, Pereira DC, Lutz L, de Souza ÂC, Dos Santos JN, Guerra RR, Medeiros GS, Santoro L, Falci DR, Rigatto MH, Barth AL, Martins AF, Zavascki AP.
    J Glob Antimicrob Resist; 2024 Sep 01; 38():247-251. PubMed ID: 38936472
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae.
    Zhang W, Guo Y, Li J, Zhang Y, Yang Y, Dong D, Zhu D, He P, Hu F.
    Antimicrob Resist Infect Control; 2018 Sep 01; 7():142. PubMed ID: 30479755
    [Abstract] [Full Text] [Related]

  • 11. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
    Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ.
    Antimicrob Agents Chemother; 2017 Mar 01; 61(3):. PubMed ID: 28031201
    [Abstract] [Full Text] [Related]

  • 12. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China.
    Han R, Shi Q, Wu S, Yin D, Peng M, Dong D, Zheng Y, Guo Y, Zhang R, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group.
    Front Cell Infect Microbiol; 2020 Mar 01; 10():314. PubMed ID: 32719751
    [Abstract] [Full Text] [Related]

  • 13. Klebsiella pneumoniae carbapenemase (KPC) in urinary infection isolates.
    Bedenić B, Sardelić S, Bogdanić M, Zarfel G, Beader N, Šuto S, Krilanović M, Vraneš J.
    Arch Microbiol; 2021 May 01; 203(4):1825-1831. PubMed ID: 33507339
    [Abstract] [Full Text] [Related]

  • 14. Molecular characterization of carbapenem and ceftazidime-avibactam-resistant Enterobacterales and horizontal spread of bla NDM-5 gene at a Lebanese medical center.
    Sobh G, Araj GF, Finianos M, Sourenian T, Hrabak J, Pappagianitsis CC, Chaar ME, Bitar I.
    Front Cell Infect Microbiol; 2024 May 01; 14():1407246. PubMed ID: 38962322
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of imipenem/relebactam and ceftazidime/avibactam against carbapenem-resistant Klebsiella pneumoniae from blood cultures in a University hospital in Serbia.
    Zornic S, Petrovic I, Lukovic B.
    Acta Microbiol Immunol Hung; 2023 Sep 21; 70(3):187-192. PubMed ID: 37535440
    [Abstract] [Full Text] [Related]

  • 16. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS.
    Int J Antimicrob Agents; 2021 Nov 21; 58(5):106439. PubMed ID: 34547421
    [Abstract] [Full Text] [Related]

  • 17. Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae.
    Wilson WR, Kline EG, Jones CE, Morder KT, Mettus RT, Doi Y, Nguyen MH, Clancy CJ, Shields RK.
    Antimicrob Agents Chemother; 2019 Mar 21; 63(3):. PubMed ID: 30617090
    [Abstract] [Full Text] [Related]

  • 18. Emergence of ceftazidime-avibactam resistance in blaKPC-33-harbouring ST11 Klebsiella pneumoniae in a paediatric patient.
    Zhou J, Yan G, Tang C, Liu J, Fu P, Ding L, Yang W, Guo Y, Wang C, Lu G, Hu F.
    Int J Antimicrob Agents; 2024 Jun 21; 63(6):107163. PubMed ID: 38570018
    [Abstract] [Full Text] [Related]

  • 19. ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime.
    Jacobs MR, Abdelhamed AM, Good CE, Mack AR, Bethel CR, Marshall S, Hujer AM, Hujer KM, Patel R, van Duin D, Fowler VG, Rhoads DD, Six DA, Moeck G, Uehara T, Papp-Wallace KM, Bonomo RA.
    Antimicrob Agents Chemother; 2024 Sep 04; 68(9):e0075124. PubMed ID: 39133021
    [Abstract] [Full Text] [Related]

  • 20. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
    Zheng M, Li FH, Liu J, Li WJ, Yin RX, Cai DT, Andrey DO, Zheng SL, Gales AC, Zhang WJ, Sun J, Liao XP, Yu Y.
    J Antimicrob Chemother; 2024 May 02; 79(5):1069-1080. PubMed ID: 38526879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.